Sentences with word «urothelial»
The word "urothelial" refers to something related to or connected with the urothelium. Urothelium is a type of tissue or lining that covers the inside of the urinary system, such as the bladder, ureters, and urethra. So, "urothelial" is basically a term used to describe things associated with the lining of these organs in our urinary system. Full definition
A Randomized, Double - Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First - line Chemotherapy in Patients with Metastatic Urothelial Cancer
vicc.org
I am a urologic oncologist and surgeon - scientist focused on using modern scientific tools to improve the management of urothelial cancers of the bladder and upper tract.
A Randomized Phase 2 Trial of Cisplatin / Gemcitabine with or without VX - 970 in Metastatic Urothelial Carcinoma
Cytology detected upper tract urothelial cancers in only 10 percent of those patients.
In summary, our study demonstrates that inactivating mutations of KDM6A, which are common in urothelial bladder carcinoma, are potentially targetable by inhibiting EZH2.
A normal bladder has three layers: On the outside is muscle, in the middle is collagen, and the innermost layer consists of specialized urothelial cells that are impermeable to urine and protect the body from waste fluids.
The main purpose of this study is to assess how metastatic or surgically unresectable urothelial carcinoma with FGF / FGFR alterations responds to treatment with the study drug, INCB054828.
Researchers at The Johns Hopkins Kimmel Cancer Center have developed a test for urine, gathered during a routine procedure, to detect DNA mutations identified with urothelial cancers.
In urothelial bladder carcinoma, KDM6A (a H3K27 demethylase) is frequently mutated, but its functional consequences and therapeutic targetability remain unknown.
The patients all had advanced urothelial cancer that had already been treated with platinum - based chemotherapy.
Consequently, we targeted EZH2 (an H3K27 methylase) and demonstrated that KDM6A - null urothelial bladder carcinoma cell lines were sensitive to EZH2 inhibition.
Further transcriptome analysis found multiple deregulated pathways, especially PRC2 / EZH2, in KDM6A - mutated urothelial bladder carcinoma.
We are investigating how chromatin modifier mutations act to promote urothelial cancer development and potentially render these cancers susceptible to novel drug combinations.
Chronic bladder infection also leads to inflammation and can manifest Urothelial Carcinoma.
Breeds at risk for developing urothelial carcinoma include Scottish Terriers, West Highland White Terriers, beagles, and Shetland sheepdogs.
The relatively low incidence of prostate cancer in intact dogs may suggest that testicular hormones Page 4 of 12 are in fact protective against ductal / urothelial prostatic carcinoma, or may have indirect effects on cancer development by changing the environment in the prostate.»
Based on their results, the researchers suggest a cause - and - effect relationship: «this suggests that castration does not initiate the development of prostatic carcinoma in the dog, but does favor tumor progression» 5 and also «Our study found that most canine prostate cancers are of ductal / urothelial origin....
TCC is also called urothelial carcinoma.
Canine TCC is almost identical to human invasive TCC (invasive urothelial carcinoma) in histopathologic characteristics, molecular features studied to date, biologic behavior (sites and frequency of metastasis), and response to medical therapy.
Saline diuresis and the thiol compound mesna were used to prevent urothelial toxicity.
AA is implicated in multiple cancer types, sometimes with very high mutational burdens, especially in upper tract urothelial cancers (UTUCs).
After a biopsy, Atala teased apart the three layers, cultivating the muscle and urothelial cells separately and discarding the collagen.
Participants have been asked to take part in this research study because they have metastatic or surgically unresectable urothelial cancer with FGF / FGFR alterations.
Roche said a phase III IMvigor211 study that evaluated the drug in people with locally advanced or metastatic urothelial cancer whose disease progressed during or after treatment with chemotherapy «did not meet its primary endpoint of overall survival compared to chemotherapy.»
Our lab is focused on understanding the effects of chromatin modifier mutations on the initiation and progression of urothelial cancers of the bladder and upper tract.
Dr. Adjei and colleagues evaluated the agent's safety, tolerability, pharmacokinetics, immunoactivity and preliminary antitumor activity in patients with a number of different advanced cancers, including colorectal, non-small-cell lung, anal and urothelial bladder tumors.
Of 56 patients with upper tract urothelial cancer, 75 percent tested positive using UroSEEK, including 79 percent of those with noninvasive tumors.
We are also examining how gene expression changes caused by chromatin modifier mutations interact with other commonly mutated pathways in urothelial cancers such as RTK - RAS - RAF and PI3K - AKT - MTOR to influence therapeutic response and resistance.
A Phase 2, Open - Label, Single - Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF / FGFR Alterations
Bladder (urothelial) cancer is the seventh most common cancer in men and the seventeenth most common in women worldwide.
In a second, late - breaking presentation, Dr Andrea Necchi, attending physician in the Department of Medical Oncology at the Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, said results from the phase III KEYNOTE - 045 trial showed that treatment with pembrolizumab resulted in longer overall survival with fewer side - effects for patients with previously treated advanced bladder (urothelial) cancer compared with patients given chemotherapy.
The inside of the scaffold was covered with her urothelial cells.
Saying current noninvasive approaches for detection of urothelial cancer are suboptimal, researchers wanted to develop a test for bladder and UTUC cancer that would allow it to be found sooner and cheaper than current methods using cytology, which is not particularly sensitive and does not do well in detecting low - grade bladder cancer or UTUC.
UroSEEK uses urine samples to seek out mutations in 11 genes or the presence of abnormal numbers of chromosomes that would indicate the presence of DNA associated with bladder cancer or upper tract urothelial cancer (UTUC).
He described the procedure to Luke and his parents: He would take some healthy cells from Luke, urothelial cells that line the urinary tract and bladder.
An Open Label, Multicenter, Single Arm Phase II Pilot Study to Evaluate the Efficacy and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK - 228), in Patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract whose Tumors Harbor a TSC1 and / or a TSC2 Mutation
A Phase III, Multicenter, Randomized, Placebo - Controlled Study of Atezolizumab (ANTI − PD - L1 Antibody) as Monotherapy and in Combination with Platinum - Based Chemotherapy in Patients with Untreated Locally Advanced or Metastatic Urothelial Carcinoma
The US Food and Drug Administration granted accelerated approval to avelumab (Bavencio) in May 2017, for the treatment of locally advanced or metastatic urothelial carcinoma patients whose disease progressed on or following platinum - containing chemotherapy.
Alterations to DDR genes were associated with improved outcomes in patients with metastatic urothelial carcinoma who were treated with immunotherapy.
The designation is specifically for patients with locally advanced or metastatic urothelial cancer who have previously been treated with immune checkpoint inhibitors.
In recent years, a number of new agents have been approved for treatment of urothelial carcinoma.
«The FDA Breakthrough Therapy designation underscores the potential of enfortumab vedotin as a meaningful treatment for patients with locally advanced or metastatic urothelial cancer,» said Robert Lechleider, MD, the vice president of clinical development at Seattle Genetics, according to a press release.
April 4, 2016 Precision medicine brings new hope to those with advanced urothelial cancer Five of six patients with advanced metastatic urothelial cancer and at least one of two specific genetic abnormalities, responded to treatment with afatinib, which was approved in 2013 by the Food and Drug Administration for patients with lung cancer, researchers report online in the Journal of Clinical Oncology.
Inclusion Criteria: • Histologically documented metastatic or surgically unresectable urothelial carcinoma; may include primary site from ureters, upper tract, renal pelvis, and bladder.
• Documented FGF / FGFR alteration and have either 1a) failed at least 1 previous treatment for their metastatic or surgically unresectable urothelial carcinoma (ie, chemotherapy, immunotherapy) or 1b) have not received chemotherapy due to poor ECOG status or 2) have insufficient renal function.
Research Interests: bladder cancer; upper tract urothelial cancer; epigenetics; chromatin; histones; methylation; drug response; drug resistance; urology
Chromatin modifiers control how DNA is organized inside a cell's nucleus, and they are mutated in the majority of urothelial cancers.
Molecular characterization data from The Cancer Genome Atlas and other groups demonstrate that almost all urothelial carcinomas of the bladder harbor a chromatin modifier gene mutation.
No expansion cohort in pancreatic cancer is being conducted, but phase II expansions are now ongoing in patients with NSCLC, SCCHN, urothelial carcinoma, melanoma, gastric or gastroesophageal junction cancer, and triple - negative breast cancer.